At OrphAI Therapeutics, we are focused on identifying and developing treatments for conditions with unmet medical need. Our current drug candidates target several disorders including Group 1 and Group 3 pulmonary hypertension, bronchiolitis obliterans post lung transplant, and SWI/SNF mutated or dysregulated cancers.
